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The myelocytomatosis oncogene (MYC) is an important driver in a sub-
type of pancreatic ductal adenocarcinoma (PDAC). However, MYC
remains a challenging therapeutic target; therefore, identifying druggable
synthetic lethal interactions in MYC-active PDAC may lead to novel pre-
cise therapies. First, to identify networks with hyperactive MYC, we pro-
filed transcriptomes of established human cell lines, murine primary PDAC
cell lines, and accessed publicly available repositories to analyze transcrip-
tomes of primary human PDAC. Networks active in MYC-hyperactive
subtypes were analyzed by gene set enrichment analysis. Next, we per-
formed an unbiased pharmacological screen to define MYC-associated vul-
nerabilities. Hits were validated by analysis of drug response repositories
and genetic gain- and loss-of-function experiments. In these experiments,
we discovered that the proteasome inhibitor bortezomib triggers a MYC-
associated vulnerability. In addition, by integrating publicly available data,
we found the unfolded protein response as a signature connected to MYC.
Furthermore, increased sensitivity of MYC-hyperactive PDACs to borte-
zomib was validated in genetically modified PDAC cells. In sum, we pro-
vide evidence that perturbing the ubiquitin–proteasome system (UPS)
might be an option to target MYC-hyperactive PDAC cells. Our data pro-
vide the rationale to further develop precise targeting of the UPS as a sub-
type-specific therapeutic approach.
Abbreviations
4-OHT, 4-hydroxytamoxifen; ATF4, activating transcription factor 4; BET, bromodomain and extra terminal motif; CTD2, cancer target
discovery and development network; depmap, dependency map; DoRothEA, discriminant regulon expression analysis; GSEA, gene set
enrichment analysis; ICGC, international cancer gene consortium; MYC, myelocytomatosis oncogene; PDAC, pancreatic ductal
adenocarcinoma; PERK, protein kinase RNA-activated-like ER kinase; SUMO, small-ubiquitin-like modifier; TCGA, the cancer genome atlas;
UPR, unfolded protein response; UPS, ubiquitin–proteasome system.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is estimated
to become the second leading cause of cancer-related
death. In contrast to other solid tumors, its prognosis
still remains extremely poor [1]. The disease is character-
ized by a profound intertumoral heterogeneity [2]. Based
on various technologies including mRNA sequencing,
metabolite profiling, or exon sequencing, distinct molec-
ular subtypes of PDAC associated with different prog-
nosis, biology, and therapeutic responses have been
described [2–13]. These data suggest the development of
biomarker-driven therapeutic concepts as a promising
approach to improve the outcome of the disease. Signa-
tures predicting sensitivity toward the current standard
of care chemotherapies are under development [12].
Whole-exome sequencing of microdissected PDAC
specimen revealed that amplification of MYC (c-MYC)
is the only copy number variation associated with lower
survival rates [14]. These data demonstrate that myelo-
cytomatosis oncogene (MYC) drives an aggressive sub-
type of the disease and consistently MYC activity was
found to be enriched in the squamous/basal-like/gly-
colytic subtype [7,13]. MYC is involved in a variety of
biological processes in cancer cells [15]. It is a prominent
oncogene acting in concert with mutated KRAS in
PDAC [16–18]. The transcription factor MYC is an
intrinsically disordered protein. Although progress has
been made to target MYC [19,20], it remains a chal-
lenge. A strategy to target ‘undruggables’ is to exploit
specific cellular dependencies associated with the activ-
ity of these proteins [21]. Several unbiased genetic
screens for synthetic lethal interactions have demon-
strated that the MYC protein family confers targetable
dependencies [22–26], pointing to a way to define precise
therapies. Consistently, MYC has been connected to the
increased sensitivity of bromodomain and extra termi-
nal motif (BET) inhibitors [27,28] and inhibitors of the
small-ubiquitin-like modifier (SUMO) pathway in the
context of PDAC [29].
To find MYC-associated vulnerabilities, we con-
ducted a limited drug screen and found a connection
of MYC to the unfolded protein response (UPR) and
an increased sensitivity toward proteasome inhibitors.
2. Materials and methods
2.1. Analysis of publicly available expression
data, drug sensitivity data, and clinical data
RNA-expression data of pancreatic cancer cell lines,
included in the CCLE dataset (19Q3), were
downloaded from the depmap data portal (https://de
pmap.org/). Drug sensitivities of human PDAC cell
lines from the PRISM repurposing primary screen
(19Q3) [30], the GDSC2 screen (AUC) [31], and the
CTD2 (AUC) screen [32] were directly accessed and
downloaded via the depmap data portal. Bortezomib
sensitivity of the lines was divided into quartiles, and
the most sensitive quartile was investigated for path-
way enrichment using gene set enrichment using the
complete CCLE-PDAC dataset. For the analysis of
drug-MYC interactions, we accessed the Discriminant
Regulon Expression Analysis (DoRothEA) database
[33] (http://dorothea.opentargets.io/) and extracted sig-
nificant (FDRq < 0.05) drug hits, which are sensitive
in cells with an increased MYC expression. Drug hits
were summarized in drug classes and compared with
hits of our experimental drug screening in a Venn dia-
gram.
PDAC transcriptome datasets of the cancer genome
atlas (TCGA) were curated according to Peran et al.
[34] (n = 150) and mRNA expression data and clinical
data were accessed via the GDC data portal
(https://portal.gdc.cancer.gov/) [35]. The international
cancer gene consortium (ICGC) dataset was down-
loaded from the supplemental data of [7]. Acinar cell
carcinomas and intraductal papillary mucinous neo-
plasms were excluded (n = 81). TCGA and ICGC
datasets were clustered using ClustVis [36] using Eucli-
dean for distance and the Ward method. The datasets
were clustered according to the genes of the HALL-
MARK-MYC-TARGET_V1, HALLMARK-MYC-
TARGET_V2, and the direct MYC targets determined
by Muhar et al. [37]. PDAC identified by all three sig-
natures were considered as common MYChigh PDACs.
For the TCGA dataset clustered by HALLMARK-
MYC-TARGET_V1, a cluster with incomplete high
expression of the target genes was recognized and
included in the MYChigh group according to this gene
set. Survival data were assigned to the commonly
MYChigh PDAC subtype and displayed in a Kaplan–
Meier curve. For subtype association of the common
MYChigh PDAC, the subtyping of Bailey et al. [7] was
used and the pancreatic progenitor subtype, ADEX
subtype, and the immunogenic subtype were combined
and depicted as nonsquamous. The TCGA dataset was
subtyped according to the identifier published by Mof-
fitt et al. [38]. RNA-seq data of untreated and 4-OHT
treated IMIM-PC1MYCER cells were described [29] and
can be accessed via NCBI/GEO: GSE119423. Enrich-
ment analysis of gene sets was performed using the
gene set enrichment analysis (GSEA) tool with default
parameters (weighted) depending on sample size ver-
sion 4.0.3 with signatures of the Molecular Signatures
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Database v7.0 and the MYC target gene set from
Muhar et al. [37]. The false discovery rate (FDR) q-
values and normalized enrichment scores (ES) are
depicted in the figures. The signature: ATF4 HUMAN
TF ARCHS4 COEXPRESSION was downloaded via
the EnrichR database [39]. In addition to the weighted
GSEA, we performed an unweighted analysis of gene
sets using the web tool GeneTrail2 1.6 [40]; multiple
testing was corrected according to [41] and displayed
as adjusted P-value.
2.2. Cell lines, CRISPR/Cas9-mediated knockout
Cell lines were cultured in high glucose Dulbecco’s
Modified Eagle Medium (DMEM; Sigma-Aldrich,
Darmstadt, Germany) or RPMI (Life Technologies,
Darmstadt, Germany) supplemented with 10% (v/v)
FCS (Merck Millipore, Berlin, Germany) and 1% (v/
v) penicillin/streptomycin (Life Technologies). All mur-
ine pancreatic cancer cell lines were established from
KrasG12D-driven mouse models of pancreatic cancer
and cultivated as described [42]. Identity of the murine
pancreatic cancer cell lines was verified by genotyping
PCR. All human cell lines (Panc1, DanG, PaTu8988S,
PSN1, PaTu8988T, MiaPaCa-2, IMIM-PC1, HPAC,
HuPT4) were authenticated by Multiplexion (Multi-
plexion GmbH, Heidelberg, Germany). To screen for
mycoplasma contamination, all cell lines are tested by
PCR as described [43]. The dual recombinase system
[44] was used to generate a murine PDAC cell line
allowing to delete floxed Myc alleles [45] by a tamox-
ifen activatable Cre (CREERT2). Alleles and genotyp-
ing for this murine PDAC cell line were recently
described [46] and the PPT-MW1955 line corresponds
to the following genotype: Pdx1-Flp;FSF-KrasG12D/+;
FSF-R26CAG-CreERT2/+;Myclox/lox. The murine cell line
PPT-9091 was transduced with the pBabepuro-myc-
ER construct, which was a gift from Wafik El-Deiry
(Addgene plasmid # 19128; http://n2t.net/addgene:
19128; RRID:Addgene_19128) as described [29].
IMIM-PC1MYCER cells were described recently [29].
To generate the CRISPR/Cas9-mediated NOXA
knockout, the protein coding region of NOXAs exon
two was targeted by two sgRNAs (sg#1: T C G A G
T G T G C T A C T C A A C T C; sg#2: T G T A A
T T G A G A G G A A T G T G A), which were
cloned into the pKLV-U6gRNA(BbsI)-PGKpur-
o2ABFP vector which was a gift from Kosuke Yusa
(Addgene plasmid # 50946; http://n2t.net/addgene:
50946; RRID: Addgene_50946). MiaPaCa2 cells were
co-transfected with a Cas9 expressing px330 vector
and the two guides or the pKLV backbone only. Posi-
tive transfected MiaPaCa-2 cells were grown under
puromycin treatment (1 µgmL1) for 2 weeks. Subse-
quently, single clones were generated, isolated, and
screened via PCR for knockout clones. The primer set:
C A C T A G T G T G G G C G T A T T A G G
(FW) + G A T G T A T T C C A T C T T C C G T
T T C C (RV1) reveals a product of 157 bp for knock-
out cells and 342 bp for wild-type cells (data not
shown). To further test whether both alleles are
deleted the primer set: FW + G T T C A G T T T G
T C T C C A A A T C T C C (RV2) was used; here,
a product at 137 bp is amplified if the cells harbor a
NOXA allele and no product if the cells harbor a
knockout for NOXA.
2.3. Cell lysis and western blot
To prepare whole-cell extracts RIPA buffer (50 mM
Tris, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, pH 8.0) supplemented with
protease and phosphatase inhibitors (protease inhibitor
cocktail complete EDTA free; Roche Diagnostics,
Mannheim, Germany, and Phosphatase-Inhibitor-Mix
I; Serva, Heidelberg, Germany) was used. Whole-cell
extracts were normalized for protein and heated at
95 °C for 5 min in protein loading buffer (45.6 mM
Tris/HCl pH 6.8, 2% SDS, 10% glycerol, 1% b-mer-
captoethanol, 0.01% bromophenol blue) and loaded
onto 10–12% SDS/PAGE and proteins were trans-
ferred to nitrocellulose membranes (Merck Millipore).
Afterward, membranes were blocked in blocking buf-
fer (5% skim milk, 0.1% Tween in PBS) and incu-
bated with b-Actin (#A5316; Sigma-Aldrich), GAPDH
(ACR001PS A160270BH; Acris, Herford, Germany),
MYC (#9402; Cell Signaling, Danvers, MA, USA),
NOXA (ALX-804-408-C100; Enzo Life Science, Farm-
ingdale, NY, USA) and cleaved PARP (552596; BD
Pharmingen, San Diego, CA, USA) primary antibod-
ies. After overnight incubation (4 °C) with primary
antibodies, membranes were incubated with DyLightTM
680 (#5366S; Cell Signaling) or 800 (#5151S; Cell Sig-
naling) conjugated secondary antibodies (1 : 10 000
dilution). NOXA and GAPDH blots have been per-
formed by chemiluminescence: secondary antibody
Licor WesternSure HRP goat anti-mouse IgG; sub-
strate: Thermo Scientific SuperSignalTM West Pico
PLUS Chemiluminescent Substrate (ThermoFisher,
Darmstadt, Germany). Western blots were visualized
by the Odyssey Infrared Imaging System (Licor, Bad
Homburg, Germany) and quantified using the IMAGE
STUDIO LITE Software V 5.2.5 (Licor). Cleaved PARP
and MYC expression values were normalized on b-
actin expression and final expression values were calcu-
lated out of three biological replicates.
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2.4. Quantitative real-time PCR
To isolate RNA from cell lines, we followed the manu-
facturer’s instructions of the Maxwell 16 LEV simply
RNA Kit (# AS1280) (Promega, Walldorf, Germany).
Quantification of mRNA was performed using the
BRYT Green Dye (GoTaq qPCR, #A600A; Pro-
mega) in a real-time PCR analysis system (StepOne-
Plus, Real-Time PCR System; Applied Biosystems
Inc., Carlsbad, CA, USA). Primers used (50–30): Myc:
T T C C T T T G G G C G T T G G A A A C
(FW)/ G C T G T A C G G A G T C G T A G T C
G (RV), Odc1: A C A T C C A A A G G C A A A G
T T G G (FW)/ A G C C T G C T G G T T T T G
A G T G T (RV), Cad: C T G C C C G G A T T G
A T T G A T G T C (FW)/ G G T A T T A G G C
A T A G C A C A A A C C A (RV) Gapdh: G G G
T T C C T A T A A A T A C G G A C T G C
(FW)/ T A C G G C C A A A T C C G T T C A C
A (RV). Data analysis was carried out with StepOne
software 2.3 Life Technologies/Applied Biosystems/
ThermoFisher) by the DDCt method (as housekeeping
gene Gapdh was used) as described [29].
2.5. Compounds
The anticancer compound library with n = 129 drugs
was obtained as a plated compound set from the NCI/
DTP Open Chemicals Repository (NCI/DTP, MD,
USA); the full list of compounds is shown in Table S3.
Bortezomib was purchased from LC-Laboratories
(Woburn, MA, USA), marizomib was purchased from
Cayman Chemicals (Ann Arbor, MI, USA), and 4-hy-
droxytamoxifen (4-OHT) was purchased from Sigma
(Sigma, Munich, Germany).
2.6. Drug screening experiment
For the drug screen, we adapted a recent screening
approach [47]. In an attempt to select for drugs highly
active in PDAC, we screened PaTu-8988S, Panc1,
DanG, and PSN1 cells with a single dose of 600 nM of
each drug. Screening was conducted in a 96-well for-
mat. Twenty-four hours after the seeding (3000 cells
per well), cells were treated with the drugs of the anti-
cancer compound library for additional 72 h. After-
ward, viability was measured with MTT assays as a
read-out for the responsivity. The screen was per-
formed as biological triplicates conducted as technical
triplicates. The mean response in the MYChigh models
was divided by the mean response in the MYClow
models. Drugs were ranked according to the ratio and
a ratio > 2 was defined as a hit.
2.7. Viability assay, clonogenic assay, and
caspase 3/7 assay
Thirty-eight recently characterized [48] murine PDAC cell
lines driven by KrasG12D/+ were termed as PDAC KC cell
lines. Cell lines were seeded in a 96-well format. Twenty-
four hours after the seeding (1500 cells per well), cells were
treated with the respective drugs for additional 72 h.
Afterward, viability was measured with MTT assays as a
read-out for the responsivity. 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Sigma, Munich) was
used in a dilution of 5 mgmL1. Ten microlitre of this
MTT solution was added per well and incubated for 4 h at
37 °C. Subsequently, the medium was removed and the
formazan crystals dissolved in 200 µLDMSO : EtOH (v/
v) and incubated for 10 min on a horizontal shaker.
Absorption was measured at 595 nm on a Thermo/
LabSystem Multiskan RC Microplate Reader (Artisan
TechnologyGroup, Champaign, IL, USA).
In addition to MTT assay, cellular viability was
measured by CellTiter-Glo ATP Viability Assay.
Briefly, 25 µL CellTiter-Glo reagent purchased
from Promega (Fitchburg, WI, USA) was added to each
well of a 96-well plate 72 h after drug treatment. After
10 min of gentle shaking and 20 min of incubation at
room temperature, luminescence was measured on a
FLUOstar OPTIMA microplate reader (BMG Labtech,
Ortenberg, Germany). The growth inhibitory 50%
(GI50) concentration was calculated with GRAPHPAD
PRISM 6 (GraphPad Software, San Diego, CA, USA)
using a nonlinear regression model. For the clonogenic
assay, 2000 MiaPaCa-2 cells (wild-type or NOXA
knockout) were seeded in 12-well plates. After 24 h,
cells were treated once with the indicated doses of borte-
zomib followed by culturing for 14 days in DMEM
(Sigma-Aldrich) supplemented with 10% (v/v) FCS
(Merck Millipore) and 1% (v/v) penicillin/streptomycin
(Life Technologies). Afterward, the medium was care-
fully removed, and cells were washed three times with
PBS. The colonies were stained with 0.2% crystal violet
solution (Sigma-Aldrich/Merck) for 20 min on a shaker
at room temperature. To remove background staining,
the wells were washed three times with tap water, dried,
and subsequently visualized using a flatbed scanner. To
determine activity of the effector caspases 3 and 7, we
performed a luminescent-based Caspase-Glo 3/7 assay
(G8090) from Promega (Fitchburg) and followed the
manufacturers’ instructions.
2.8. Statistical methods
All experiments were conducted in biological triplicates
unless otherwise stated in the figure legends. ANOVA
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or two-sided Student’s t-test was used to investigate sta-
tistical significance, as indicated. P-values were calcu-
lated with GRAPHPAD PRISM 6/8 (GraphPad Software)
and corrected according to Bonferroni for multiple test-
ing unless otherwise indicated. P-values are indicated or
* in the figures denotes P < 0.05. Fisher’s exact test,
was used to assess the association between PDAC sub-
types and the expression of MYC target genes.
3. Results
3.1. Drug screening of FDA-approved anticancer
drugs identifies vulnerabilities in MYChigh human
PDAC cells
To identify vulnerabilities in PDACs with an increased
MYC activity, we performed an unbiased pharmacolog-
ical drug screening experiment. Based on publicly avail-
able transcriptional datasets (CCLE), we first identified
cell lines with high and low MYC activity and selected
four representative cell lines (two MYChigh, two
MYClow). Western blots of MYChigh cell lines demon-
strated higher MYC protein expression and enrichment
of relevant MYC signatures in GSEA of mRNA expres-
sion profiles (Fig. 1A). Except for PSN1, the doubling
time of the cell lines was in similar ranges (Table S1).
GSEA with the GeneTrail2 1.6 web service [40] demon-
strated the activation of the MYC network in cells with
higher expression of the protein (Fig. 1B). A novel gene
set of direct MYC target genes defined by Muhar et al.
[37] showed the strongest enrichment in the MYChigh
cell lines (Fig. 1B). We used the described models for a
drug screening experiment with a set of 129 FDA-ap-
proved anticancer drugs, which is outlined in Fig. 1C.
Hits were determined as a twofold difference in the
responsiveness of the MYChigh models. Among the ten
candidates, we identified drugs from different classes,
such as HDAC inhibitors, DNA antimetabolites, pro-
teasome inhibitors, topoisomerase inhibitors, and others
(Fig. 1D and Table S2).
3.2. Validation experiments confirm drug
screening results
To validate the single-dose drug screening experiment,
we again examined the top 11 hits of our screening
experiment using different doses and determined the
dose–response curves. In addition to the used screening
platform, we included two more PDAC lines with low
MYC protein expression (HPAC, HuPT4) and two
PDAC lines with intermediate/high MYC expression
(MiaPaCa2, PaTu8988T). As shown in Fig. 2A, MYC
protein expression is significantly different in the ana-
lyzed cell lines. Most dose–response curves were all left-
shifted in the MYChigh models (Fig. 2B). Despite the
low MYC expression in HPAC cells, these cells cluster
into the MYChigh high group and show increased sensi-
tivity, which could be explained by expression of func-
tional wild-type p53. Although the mean area under the
dose–response curves (AUC) is lower for all screening
hits in the MYChigh models, a high variance was
detected (Fig. 2B). Such observations point to the need
for large cell line panels to ultimately validate screening
hits. Therefore, to further substantiate the screening
hits, we accessed the DoRothEA database [33]. This
database links the transcriptional activity of 127 tran-
scription factors to drug sensitivity. We accessed the
data for MYC and found significant overlaps of six drug
classes with our screening experiment, which points to
the robustness of the screen (Fig. 2C).
3.3. MYC-associated pathways in human PDAC
To prioritize the hits of the screen, we accessed human
PDAC mRNA expression datasets to observe potential
connections of MYC-associated pathways to the
screening hits. We used a PDAC data set from TCGA
[35], which was curated according to Peran et al.
(n = 150) [34]. In addition, we used the ICGC dataset
[7], in which acinar cell carcinomas and intraductal
papillary mucinous neoplasms were excluded (n = 81).
We clustered both datasets according to the HALL-
MARK_MYC_TARGET_GENES_V1, the HALL-
MARK_MYC_TARGET_GENES_V2, and the
MUHAR_MYC_TARGETS, as exemplified for the
ICGC dataset in Fig. 3A. Eight cancers (~ 10%) were
defined as MYC hyperactivated by all three MYC sig-
natures (Fig. 3A,B). These cancers showed a reduced
survival (Fig. S1A) and a clear connection to the squa-
mous subtype of the disease (Figs 3A and S1B). Using
the same approach for the TCGA dataset, 16 cancers
(~ 10%) were defined to be MYC hyperactivated by
all three used MYC signatures (Fig. S1C). Although
survival of MYC hyperactivated cancers was not
reduced in this dataset (Fig. S1D), a connection to the
basal-like cancer was again observed (Fig. S1E), which
confirms the documented connection of MYC to this
subtype of PDAC [7,49]. To define MYC-associated
pathways in the commonly MYC hyperactivated sub-
type, we performed a GSEA. Six hundred and three
signatures were consistently enriched in both analyzed
dataset when HALLMARKS-, KEGG-, GO-Term-,
and REACTOME signatures were accessed via the
MSigDB (Fig. 3C). Figure 3D shows HALLMARK
and KEGG signatures linked to MYC in both
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datasets. To corroborate the direct connection of such
pathways, we used a MYC estrogen receptor fusion
protein (MYCER) of IMIM-PC1 cells, which are char-
acterized by low MYC protein abundance [29]. Here,
MYC-activated signatures show an overlap to the
HALLMARK and KEGG signatures detected in the
analysis of the ICGC and TGCA datasets, pointing to
direct effects of MYC (Fig. S1F). Investigating the
MYC-connected signatures, we detected a prominent
proportion of ribosomal and translational signatures
in both datasets, which is well in line with a recent
analysis of the TCGA dataset demonstrating that
translation is a key process linked to MYC in PDAC
[50]. Consistent with increased translational activity,
we detected signatures of the UPR and UPR-activated
signaling, including protein kinase RNA-activated-like
Fig. 1. Drug screening in human PDAC cells with diverse MYC activity. (A) MYC protein expression analysis of the four indicated PDAC cell
lines was determined by western blotting. b-Actin (actin) served as a loading control. (B) GSEA by GeneTrail2 1.6 web service demonstrates
enrichment of the depicted MYC signatures in the MYChigh lines. Color-coded ES is depicted. *** adjusted P values < 0.001; **** adjusted
P values < 0.0001. (C) Strategy for drug screening experiments with n = 129 FDA-approved anticancer drugs. Cells were treated for 72 h
(two doubling times) with 600 nM of each compound. Hits were determined as a twofold difference in responsiveness. (D) Top 10 hits from





























































































































































































































































































































Fig. 2. Validation of the drug screening experiment. (A) Quantification of MYC expression of the indicated cell lines. In three independent
lysates, the MYC expression was determined and shown is the mean with SD MYC expression per cell lines. *P value of an unpaired t-test
< 0.05. (B) Viability for multidose treatment of MYChigh and MYClow cells of displayed compounds. Cells were treated for 72 h and viability
was measured by MTT. All experiments were conducted in n = 3 technical replicates in a dosage range of 0.5 nM–10 µM. Except for HPAC
(n = 1), three independent biological replicates have been performed in the depicted cell lines. The mean (with SD) area under the dose–
response curves (AUC) in both groups is depicted for each drug. (C) Venn diagram of data from the DoRothEA database and our drug
screening hits. Significant (FDRq < 0.05) drug–MYC interactions of the DoRothEA database were compared to the hits of our experimental
drug screening experiment. Drugs hits were summarized into drug classes.
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ER kinase (PERK) and activating transcription factor
4 (ATF4) signatures in both investigated human
PDAC datasets (Fig. 3E) [51].
3.4. MYC and sensitivity toward perturbants of
protein homeostasis
The observation that MYC activity is connected to
the UPR (Fig. 3D,E) and our recent demonstration
that MYC is mechanistically involved in the induction
of apoptosis in response to proteasome inhibition in
PDAC cells [52], prompted us to investigate the borte-
zomib screening hit in greater detail. First, we used
the dependency map (DepMap) portal to access
bortezomib sensitivity data for PDAC cell lines using
data from the PRISM repurposing primary screen
[30], the GDSC2 screen [31], and the cancer target
discovery and development network (CTD2) screen
[32]. We determined bortezomib-sensitive PDAC cell
lines and analyzed them by a GSEA. Consistently, in
all three datasets, we observed an enrichment of
MYC signatures in the bortezomib-sensitive pheno-
type (Fig. 4A). To validate a connection of the MYC
network to increased sensitivity toward proteasome
inhibitors across species, we performed multidose
drug screenings with the proteasome inhibitors mari-
zomib and bortezomib in 38 well-characterized murine
KrasG12D-driven PDAC cell lines [48] (Fig. 4B). The
GI50 values of both inhibitors showed a significant
correlation (Fig. 4B). We used RNA-seq data [48] of
these murine PDAC lines and investigated enrichment
of MYC signatures in bortezomib sensitive, mari-
zomib sensitive, and lines sensitive to both protea-
some inhibitors. We detected enrichment of the
MUHAR MYC TARGETS and the HALLMARK-
MYC TARGETS V2 signature enriched in all protea-
some inhibitor-sensitive phenotypes (Fig. 4C). To test
whether sensitivity of perturbants of the protein
homeostasis is commonly connected to increased
MYC activity, we analyzed the HSP90 inhibitors
ganetespib and NMS-E973, and the valosin-containing
protein (VCP)/p97 inhibitor NMS-873. Such inhibi-
tors are able to induce ER stress and the UPR [53–
56]. Two additional proteasome inhibitors, oprozomib
and ixazomib, were included as controls. To investi-
gate the connection of HSP90 inhibitors and p97 inhi-
bitors to MYC, we used again the data of the
PRISM repurposing primary screen [30]. In GSEA,
HSP90 and p97 inhibitors sensitive PDAC cell lines
enrich for MYC signatures and an UPR signature
(Fig. S1B). The same was again observed for opro-
zomib- and ixazomib-sensitive lines (Fig. S1D). These
data support the conclusion that MYC hyperactivated
PDACs are more sensitive to perturbants of the pro-
tein homeostasis.
3.5. Human PDAC cells with active MYC are
primed for bortezomib-induced apoptosis
Previously, we described that bortezomib-induced
apoptosis of PDAC cell lines is mediated by MYC-de-
pendent activation of pro-death BCL2 family mem-
bers, including NOXA (PMAIP1) [52]. To corroborate
augmented apoptosis induction as the underlying prin-
ciple for the increased sensitivity toward proteasome
inhibition in MYChigh PDAC lines, we monitored
cleavage of the caspase substrate PARP and NOXA
expression over time. Only in MYChigh lines, a signifi-
cant NOXA induction and associated cleavage of
PARP was observed eight hours after the treatment
(Fig. 4D). Twenty-four hours after the treatment,
NOXA was expressed and caspases were also activated
in MYClow cell lines (Fig. 4D). Nevertheless, borte-
zomib-induced PARP cleavage and NOXA expression
were always higher in MYChigh lines (Fig. 4E). Since
the BH3-only pro-apoptotic BCL2 family member
NOXA was recently described to contribute to borte-
zomib-induced apoptosis in PDAC cell lines [52], we
induced a CRISPR-Cas9-mediated knockout of the
NOXA gene in MiaPaCa2 cells (Fig. 4F). The thera-
peutic response toward bortezomib is distinctly
reduced in NOXA-deficient MiaPaCa2 cells (Fig. 4G-
J), demonstrating the relevance of the gene for the
bortezomib-induced apoptosis.
To analyze the direct contribution of MYC to the
proteasome inhibitor sensitivity, we used the dual
recombination system [44] with floxed Myc alleles [45]
to generate a genetic loss-of-function PDAC model
(Fig. 5A). Activation of a CreERT2 fusion by the addi-
tion of 4-OHT in this murine PDAC cell lines deleted
the floxed Myc alleles and reduces MYC protein
expression to ~ 30% compared to controls (Fig. 5B,
C). It is important to note that we were not able to
generate a complete MYC knockout, due to the pro-
found counter selection of recombination escapers,
which underscores the importance of MYC as a target
in PDAC. Nevertheless, the MYC-reduced population
was less bortezomib sensitive (Fig. 5D). In addition,
we used a conditional gain-of-function model relying
on a MYC estrogen receptor fusion (MYCER). We
transduced a murine PDAC cell line with low MYC
expression. Upon treatment with 4-hydoxytamoxifen
(4-OHT), the MYC targets Odc1 and Cad were
induced and endogenous Myc was repressed by its
negative autoregulation (Fig. 5E). Seeding the cells in
4-OHT for 24 h followed by a 3-day treatment period
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Fig. 3. Pathways enriched in human common MYChigh PDACs. (A) Clustering of the ICGC PDAC mRNA expression dataset according to the
genes of the HALLMARK_MYC_TARGETS_V1 signature. Color-coded information of the histology, the subtype, and the MYC activity state
determined by clustering of the HALLMARK_MYC_TARGETS_V1, the HALLMARK_MYC_TARGETS_V2, and the MUHAR MYC TARGETS
[37] are depicted. (B) Venn diagram of PDAC identified as MYChigh by clustering of the genes of the depicted signatures in the ICGC
dataset. Eight PDACs were identified as common MYChigh PDACs. (C) Common MYChigh PDACs of the TCGA and the ICGC dataset were
analyzed by GSEA using the HALLMARK, the KEGG, the REACTOME, and the GO-TERM signatures of the MSigDB with a FDR q value
threshold of < 0.25. The Venn diagram depicts 603 signatures enriched in common MYChigh PDACs of both datasets. (D) NES visualized by
a heatmap of the HALLMARK and the KEGG signatures enriched in common MYChigh PDACs of both datasets. (E) NES visualized by a
heatmap of gene signatures of the UPR and UPR-associated pathways enriched in common MYChigh PDACs of both datasets. As a control,
IMIM-PC1MYCER cells were used. Shown is the NES of the same signatures enriched in 4-OHT treated (MYC on) cells. For all depicted
signatures: FDR q < 0.05.
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Fig. 4. MYC primes for proteasome inhibitor-induced apoptosis. (A) Bortezomib sensitivities of human PDAC cell lines from the PRISM
repurposing primary screen (19Q3) [30], the GDSC2 screen (AUC) [31], and the CTD^2 (AUC) screen [32] were divided into quartiles and
lines for the most sensitive quartile were compared to the remaining cell lines of the complete CCLE-PDAC dataset with a GSEA using the
GeneTrail2 1.6 web service. The ES was color-coded. **** adjust. P-value < 0.0001. (B) Growth inhibitory 50% concentration of n = 38
murine PDAC cell lines for bortezomib and marizomib was determined (72 h of treatment, seven-point dilution, MTT assay, nonlinear
regression, n = 3 independent biological replicates as technical triplicates). Depicted is the Pearson correlation coefficient and the linear
regression (in red). (C) Bortezomib and marizomib GI50 values were divided into quartiles and lines from the most sensitive quartile were
compared to the remaining cell lines by GSEA. In addition, the lines belonging to the bortezomib as well as the marizomib most sensitive
quartile were compared to the rest of the lines by GSEA. GSEA was conducted by the GeneTrail2 1.6 web service. Color-coded ES is
depicted. **adj. P-value < 0.01, ***adj. P-value < 0.001, ****adj. P-value < 0.0001. (D) Different lysates were blotted (western blot) to
different membranes to determine expression of cleaved PARP, NOXA and b-actin (actin), or GAPDH as loading controls, 8 and 24 h after
treatment with 50 nM bortezomib or DMSO (vehicle control). (n = 3). (E) The cleaved PARP band was quantified in three independent
experiments and the mean fold induction of cleaved PARP expression in MYClow and MYChigh subtypes is depicted. (F) Determination of
CRISPR/Cas9 mediated knockout of the NOXA gene in MiaPaCa2 cells by PCR. A product size of 137 bp indicates the wild-type allele,
while no product indicates NOXA knockout a cells as described in MM section. (G) Western blot analysis for expression of NOXA and
cleaved PARP of MiaPaCa2 cells harboring either a NOXA wild-type expression or a NOXA knockout. b-Actin (actin) and GAPDH served as
loading controls. Cells were treated for 24 h with bortezomib (+ 50 nM, ++ 100 nM, +++ 200 nM) or treated with DMSO as vehicle control (-).
(H) Relative caspase 3/7 activity (mean with SD) of MiaPaCa2 NOXA wild-type versus NOXA knockout cells. Cells were treated for 24 h
with bortezomib (25 nM) or treated with DMSO as vehicle control (-). (I) Clonogenic growth assay of bortezomib-treated MiaPaCa-2 NOXA
knockouts and wild-type cells with the indicated concentrations. One representative experiment out of three is depicted. (J) Quantification
of three independent clonogenic growth assays (mean with SD) according to I). *P value of an unpaired t-test < 0.001.
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with bortezomib did not change the sensitivity to the
proteasome inhibitor (Fig. 5F). MYC-amplified PSN1
cells were included as a bortezomib-sensitive control.
Considering the time needed to adapt the system to
MYC, we followed two strategies. First, pretreating
the cells with 4-OHT for 24 h followed by a 6-day
treatment period with bortezomib, demonstrated
increased sensitivity in the MYC ‘on’ state (Fig. 5G).
Second, pretreating the cells with 4-OHT for 96 h fol-
lowed by 72 h of bortezomib treatment also sensitized
the cells to bortezomib (Fig. 5H). Therefore, gain- and
loss-of-function models support the note that MYC
modulates the proteasome inhibitor sensitivity of
PDAC cells.
4. Discussion
Success of cancer therapeutics substantially differs due
to a huge heterogeneity of human cancers, incomplete
understanding how drugs mechanistically act, poorly
described resistance mechanisms, or a lack of stratifi-
cation for patients, which benefit from the therapy. As
recently shown, deregulation of MYC is sufficient to
promote PDAC progression in mice [57]. Furthermore,
an aggressive PDAC subtype is associated with high
MYC activity [7] and MYC-associated vulnerabilities
can be exploited therapeutically [27,28,58]. Here, we
performed a limited unbiased pharmacological screen
and provide evidence that perturbants of the protein
homeostasis are more effective in MYC-hyperactive
PDAC cells.
Importantly, work from 2020 describes treatment
options for PDAC using perturbants of the protein
homeostasis in PDAC [59,60]. A subtype characterized
by expression of cornified/squamous-related genes, the
expression of ATF4 and CHOP, and sensitivity to the
proteasome inhibitor carfilzomib was deciphered [59].
Although such data concur with our observations, an
involvement of MYC was not investigated and the
observation was more restricted to carfilzomib, than to
other proteasome inhibitors [59].
Myelocytomatosis oncogene is well known to serve
the metabolic demands for biomass accumulation of
dividing cells, including a prominent function toward
protein synthesis through increasing ribosome biogene-
sis [61]. The relevance of MYC-induced protein syn-
thesis for its function in cancer is well documented.
Ribosomal protein haploinsufficiency impairs MYCs
oncogenic activity in the El-Myc lymphoma model
[62]. High MYC activity increases the protein load
beyond the protein folding capacity of cells and can
therefore activate UPR in mammalians and Droso-
phila [63,64]. The importance of MYC-induced UPR
is underscored by the demonstration of a synthetic
lethal interaction of MYC with components of the
UPR, including PERK and XBP1 [63,65,66]. Across
several PDAC datasets and in mechanistic conditional
MYC off/on models, we observed a connection of
MYC activity to UPR signatures, arguing that PDACs
with high MYC activity might be at the edge to die
from proteotoxicity. Although such cancer cells can
cope with the increased protein load via an adaptive
ER stress-induced survival pathway [51], they are less
able to tolerate any further increased protein chal-
lenge, contributing to our observation of increased
proteasome inhibitor sensitivity in at least some MYC-
hyperactive PDACs. Such a scenario is supported by
several layers of evidence. It was demonstrated that
PDAC cells escaping dependency on KRAS activate
the MYC network to increase protein synthesis, which
activates adaptive ER stress pathways [67]. Consistent
with our data, such PDAC cells were found to be sus-
ceptible to perturbations of protein homeostasis
induced by HSP90 or proteasome inhibitors [67].
Moreover, we found that human PDAC lines sensitive
to the VCP/p97 inhibitor NMS-873, known to trigger
a UPR [55,56], enrich for MYC signatures. The strong
connection of MYC to translation, the observed link
to the UPR, the enrichment of MYC signatures in p97
inhibitor or HSP90 inhibitor-sensitive PDAC cell lines,
and the modulation of the proteasome inhibitor
response in MYC genetic gain- and loss-of-function
models [52], argues that MYC-hyperactive PDACs are
more sensitive toward perturbations of the protein
homeostasis. Although these considerations need addi-
tional validations in context of PDAC, they are sup-
ported from clinical data in multiple myeloma, where
MYC seem to be connected to a benefit of proteasome
inhibitor-based therapy [68,69].
Although there is ample evidence that MYC gener-
ates vulnerability toward perturbants of the protein
homeostasis, it is important to note that MYC-inde-
pendent pathways can also contribute. UPR can be
induced via reactive oxygen species (ROS) whereas in
this scenario the GRP78/PERK/NRF2 axis is required
to keep cellular ROS levels low and thus prevent
apoptosis signaling [70,71]. In PDAC Nrf2 is associ-
ated with cap-dependent mRNA translation and sup-
ports PDAC maintenance [72]. The association of such
a ROS-NRF2 pathway to proteasome inhibitor sensi-
tivity in context of PDAC remains to be demonstrated.
In addition, well-described changes in NFjB signaling
[73], downregulation of anti-apoptotic proteins such as
XIAP or BCL2 [74,75] associated sensitivity to protea-
some inhibitors, an inhibition of the NFjB signaling
pathway [73], the associated downregulation of anti-
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apoptotic proteins such as XIAP or BCL2 [74], the
mutational status of the tumor suppressor p53 [76],
and aneuploidy of the cancer cells [77] indicate
increased responsivity toward proteasome inhibition.
Some PDAC xenograft in vivo models respond to
proteasome inhibitor treatment [78,79], whereas others
resist [80]. Also, for patient-derived xenografts (PdXs),
proteasome inhibitor responding and nonresponding
models have been documented [81,82]. Interestingly,
Beglyarova et al. [82] observed a proteasome inhibitor
response in a MYC-amplified PdX with high protein
expression of the oncogene, whereas the nonamplified
PdX tested in the study resisted the therapeutic inter-
vention. Such observations clearly demonstrate the
need to stratify for responsiveness toward perturba-
tions of protein homeostasis and support our note that
proteasome inhibitor sensitivity is a MYC/UPR-associ-
ated trait in PDAC. The lack of stratification might
contribute to the negative outcome of a phase II
PDAC study, where patients were treated with borte-
zomib or with the combination containing gemcitabine
and bortezomib [83].
In the neuroblastoma line SHEP, which harbors a
MYCNER transgene, an unbiased pharmacological
screen with 938 FDA-approved drugs, recently demon-
strated bortezomib, carfilzomib, cabazitaxel, pralatrex-
ate, gemcitabine, vincristine, docetaxel, paclitaxel,
etoposide, and doxorubicin to be the top ten MYCN-
associated pharmacological vulnerabilities [84]. The
substantial overlap of these hits with our screen vali-
dates the used experimental approach and demon-
strates specific vulnerabilities across the MYC family
and cross different tumor entities. As in the PDAC
context, where MYC directly activates the transcrip-
tion of the pro-death BCL2 family member NOXA
(PMAIP1) [52] upon bortezomib treatment, NOXA
Fig. 5. Proteasome inhibitor sensitivity and MYC—genetic gain and loss of function. (A) Scheme of floxed MYC alleles, which can be
deleted by CreERT2 recombinase upon treatment with 4-OHT. E1-E3: Exon 1-Exon 3; 4-OHT: 4-OHT. (B) Protein expression of MYC and b-
actin (actin, loading control) in EtOH and 4-OHT PDAC cells 72 h after treatment. Displayed are three independent biological replicates. (C)
Quantification of MYC protein expression (mean with SD), determined by western blot (n = 3). (D) Relative viability of PDAC cells, 72 h
after treatment with bortezomib. Cells were pretreated with EtOH and 4-OHT for 24 h. Viability was measured by MTT test. P value of an
unpaired t-test is depicted (mean with SD; n = 3). (E) Quantitative PCR of indicated targets 72 h after treatment with 600 nM 4-OHT. Gapdh
served as housekeeping control (mean with SD; n = 3). (F) Viability test by CellTiter-Glo of PSN1 and PPT-9091-MYCER cell lines. Two
thousand cells were seeded and after 24 h treated with 600 nM 4-OHT (MYCER shuttles into nucleus) or EtOH (vehicle) and seven
increasing concentrations of bortezomib for 3 days; highest conc.: 100 nM. (G) 6-day treatment with 600 nM of 4-OHT, and simultaneous
treatment with bortezomib 24 h after seeding of 1000 cells/well similar to (F). (H) Treatment for 3 day with 600 nM 4-OHT and subsequent
3 day treatment with bortezomib without 4-OHT treatment according to (I). For F–H, the SD was used for error bars and three independent
biological replicates were conducted as technical triplicates.
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contributes also in neuroblastoma models significantly
to the bortezomib-induced apoptosis [84].
The DoRothEA database [33] demonstrates that
MYC has the highest number of transcription factor–
drug interactions among all transcription factors ana-
lyzed [33]. Interestingly, only associations in which
MYC is sensitizing for a drug were observed in this
database [33]. Consistently, in context of PDAC, evi-
dence that MYC increases the sensitivity toward protea-
some inhibitors, BET inhibitors [27,28], SUMOylation
inhibitors [29], the ERCC3 inhibitor triptolide [82], or
cisplatin [85] was provided. However, it is important to
note that MYC was also associated with drug resistance
in PDAC. Important work has demonstrated that MYC
is involved in a ductal-neuroendocrine lineage switch,
whereby the neuroendocrine lineage resists gemcitabine
[86]. Although paclitaxel was demonstrated to trigger a
mitotic vulnerability [87], recent work, which investi-
gated paclitaxel-resistant primary PDAC cultures impli-
cates a MYC function in the resistant phenotype [88].
Interestingly, the anti-apoptotic BCL2 family member
MCL1 is co-upregulated with MYC in paclitaxel-resis-
tant PDAC cultures [88]. Anti-apoptotic BCL2 family
members are described to be relevant modulators of the
MYC-associated mitotic vulnerability [87]. Whether
BCL2 family proteins are important switches, determin-
ing MYC-mediated sensitivity or resistance in the
PDAC context awaits further detailed analysis.
5. Conclusions
As a mono- as well as in combination therapies, borte-
zomib demonstrates limited efficacy in solid cancers in
the clinic [89–91]. Furthermore, a narrow therapeutic
index and unfavorable pharmacokinetic features
[89,91], with impaired distribution to solid tumors,
may limit the clinical development of bortezomib in
PDAC. However, our data provide evidence that per-
turbation of the protein homeostasis is an option to
target MYC-active PDACs. Considering the develop-
ment of next-generation proteasome inhibitors [89], the
development of new bortezomib formulations [92], or
options to target the ubiquitin–proteasome system at
different levels [55,56,93], will allow to advance the
concept in the future.
Acknowledgements
We thank NCI/DTP Open Chemicals Repository for
providing the screening library. The results published
here are fully or partially based upon data generated
by the Cancer Target Discovery and Development
(CTD2) Network (https://ocg.cancer.gov/programs/ctd
2/data-portal) established by the National Cancer
Institute’s Office of Cancer Genomics. Part of the
results shown here is based upon data generated by
the TCGA Research Network: https://cancergenome.
nih.gov. We thank all colleagues providing plasmids
via the Addgene platform. We thank Aylin Aydemir
for excellent technical support.
This work was supported by the Else-Kr€oner-Frese-
nius-Stiftung (2016_A43 to MW), Deutsche
Forschungsgemeinschaft (DFG) [SCHN 959/3-1 to
GS; SFB1321/S01 (Project-ID 329628492) to MR, DS,
GS; SFB824/C3 to UK], Wilhelm-Sander Foundation
(2017.048.2 to UK and GS), Stiftung Charite (to UK),
Walter-Schulz-Stiftung (to MW). Open access funding
enabled and organized by Projekt DEAL.
Conflict of interest




GS, MW, and CS designed the study, analyzed, and
visualized the data and wrote the paper. KL, ZH, SL,
MJD, CS, and R€O performed, interpreted, and ana-
lyzed experiments and/or generated important model
systems. DS., RR, UK, OHK, and MR provided
important resources and critical input. All authors
read and approved the final manuscript.
References
1 Siegel RL, Miller KD & Jemal A (2019) Cancer
statistics, 2019. CA Cancer J Clin 69, 7–34.
2 Collisson EA, Bailey P, Chang DK & Biankin AV
(2019) Molecular subtypes of pancreatic cancer. Nat
Rev Gastroenterol Hepatol 16, 207–220.
3 Cancer Genome Atlas Research Network & Cancer
Genome Atlas Research Network (2017) Integrated
genomic characterization of pancreatic ductal
adenocarcinoma. Cancer Cell 32, 185–203.
4 Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O,
Moutardier V, Turrini O, Giovannini M, Bian B,
Bigonnet M et al. (2017) Pancreatic adenocarcinoma
therapeutic targets revealed by tumor-stroma cross-talk
analyses in patient-derived xenografts. Cell Rep 21,
2458–2470.
5 Noll EM, Eisen C, Stenzinger A, Espinet E,
Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler
3059Molecular Oncology 14 (2020) 3048–3064 ª 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
K. Lankes et al. Vulnerabilities in an aggressive PDAC subtype
W, Rosli C et al. (2016) CYP3A5 mediates basal and
acquired therapy resistance in different subtypes of
pancreatic ductal adenocarcinoma. Nat Med 22, 278–
287.
6 Waddell N, Pajic M, Patch AM, Chang DK, Kassahn
KS, Bailey P, Johns AL, Miller D, Nones K, Quek K
et al. (2015) Whole genomes redefine the mutational
landscape of pancreatic cancer. Nature 518, 495–501.
7 Bailey P, Chang DK, Nones K, Johns AL, Patch AM,
Gingras MC, Miller DK, Christ AN, Bruxner TJ,
Quinn MC et al. (2016) Genomic analyses identify
molecular subtypes of pancreatic cancer. Nature 531,
47–52.
8 Daemen A, Peterson D, Sahu N, McCord R, Du X,
Liu B, Kowanetz K, Hong R, Moffat J, Gao M et al.
(2015) Metabolite profiling stratifies pancreatic ductal
adenocarcinomas into subtypes with distinct sensitivities
to metabolic inhibitors. Proc Natl Acad Sci USA 112,
E4410–E4417.
9 Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd
A, Creighton S, Southwood B, Liang SB, Chadwick D,
Zhang A et al. (2018) Genomics-driven precision
medicine for advanced pancreatic cancer: early results
from the COMPASS trial. Clin Cancer Res 24, 1344–
1354.
10 Collisson EA, Sadanandam A, Olson P, Gibb WJ,
Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula
L et al. (2011) Subtypes of pancreatic ductal
adenocarcinoma and their differing responses to
therapy. Nat Med 17, 500–503.
11 Muckenhuber A, Berger AK, Schlitter AM, Steiger K,
Konukiewitz B, Trumpp A, Eils R, Werner J, Friess H,
Esposito I et al. (2018) Pancreatic ductal
adenocarcinoma subtyping using the biomarkers
hepatocyte nuclear factor-1A and cytokeratin-81
correlates with outcome and treatment response. Clin
Cancer Res 24, 351–359.
12 Tiriac H, Belleau P, Engle DD, Plenker D, Deschenes
A, Somerville TDD, Froeling FEM, Burkhart RA,
Denroche RE, Jang GH et al. (2018) Organoid profiling
identifies common responders to chemotherapy in
pancreatic cancer. Cancer Discov 8, 1112–1129.
13 Karasinska JM, Topham JT, Kalloger SE, Jang GH,
Denroche RE, Culibrk L, Williamson LM, Wong HL,
Lee MKC, O’Kane GM et al. (2019) Altered gene
expression along the glycolysis-cholesterol synthesis axis
is associated with outcome in pancreatic cancer. Clin
Cancer Res 26, 135–146.
14 Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin
WC, Mansour J, Mollaee M, Wagner KU, Koduru P,
Yopp A et al. (2015) Whole-exome sequencing of
pancreatic cancer defines genetic diversity and
therapeutic targets. Nat Commun 6, 6744.
15 Dang CV (2012) MYC on the path to cancer. Cell 149,
22–35.
16 Wirth M, Mahboobi S, Kramer OH & Schneider G
(2016) Concepts to target MYC in pancreatic cancer.
Mol Cancer Ther 15, 1792–1798.
17 Wirth M & Schneider G (2016) MYC: a stratification
marker for pancreatic cancer therapy. Trends Cancer 2,
1–3.
18 Hessmann E, Schneider G, Ellenrieder V & Siveke JT
(2016) MYC in pancreatic cancer: novel mechanistic
insights and their translation into therapeutic strategies.
Oncogene 35, 1609–1618.
19 Allen-Petersen BL & Sears RC (2019) Mission possible:
advances in MYC therapeutic targeting in cancer.
BioDrugs 33, 539–553.
20 Fletcher S & Prochownik EV (2015) Small-molecule
inhibitors of the Myc oncoprotein. Biochim Biophys
Acta 1849, 525–543.
21 Huang A, Garraway LA, Ashworth A & Weber B
(2019) Synthetic lethality as an engine for cancer drug
target discovery. Nat Rev Drug Discov 19, 23–38.
22 Cermelli S, Jang IS, Bernard B & Grandori C (2014)
Synthetic lethal screens as a means to understand and
treat MYC-driven cancers. Cold Spring Harb Perspect
Med 4, a014209.
23 Herold S, Kalb J, Buchel G, Ade CP, Baluapuri A, Xu
J, Koster J, Solvie D, Carstensen A, Klotz C et al.
(2019) Recruitment of BRCA1 limits MYCN-driven
accumulation of stalled RNA polymerase. Nature 567,
545–549.
24 Kessler JD, Kahle KT, Sun T, Meerbrey KL,
Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li
MZ, Hartman ZC et al. (2012) A SUMOylation-
dependent transcriptional subprogram is required for
Myc-driven tumorigenesis. Science 335, 348–353.
25 Toyoshima M, Howie HL, Imakura M, Walsh RM,
Annis JE, Chang AN, Frazier J, Chau BN, Loboda A,
Linsley PS et al. (2012) Functional genomics identifies
therapeutic targets for MYC-driven cancer. Proc Natl
Acad Sci USA 109, 9545–9550.
26 Hsieh AL & Dang CV (2016) MYC, metabolic
synthetic lethality, and cancer. Recent Results Cancer
Res 207, 73–91.
27 Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A,
Gilabert M, Moutardier V, Garcia S, Turrini O,
Delpero JR et al. (2017) Gene expression profiling of
patient-derived pancreatic cancer xenografts predicts
sensitivity to the BET bromodomain inhibitor JQ1:
implications for individualized medicine efforts. EMBO
Mol Med 9, 482–497.
28 Bian B, Juiz NA, Gayet O, Bigonnet M, Brandone N,
Roques J, Cros J, Wang N, Dusetti N & Iovanna J
(2019) Pancreatic cancer organoids for determining
sensitivity to bromodomain and extra-terminal
inhibitors (BETi). Front Oncol 9, 475.
29 Biederst€adt A, Hassan Z, Schneeweis C, Schick M,
Schneider L, Muckenhuber A, Hong Y, Siegers G,
3060 Molecular Oncology 14 (2020) 3048–3064 ª 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
Vulnerabilities in an aggressive PDAC subtype K. Lankes et al.
Nilsson L, Wirth M et al. (2020) SUMO pathway
inhibition targets an aggressive pancreatic cancer
subtype. Gut 69, 1472–1482.
30 Corsello SM, Nagari RT, Spangler RD, Rossen J,
Kocak M, Bryan JG, Humeidi R, Peck D, Wu X, Tang
AA et al. (2019) Non-oncology drugs are a source of
previously unappreciated anti-cancer activity. bioRxiv.
“[PREPRINT]” https://doi.org/10.1101/730119.
31 Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden
MP, Schubert M, Aben N, Goncalves E, Barthorpe S,
Lightfoot H et al. (2016) A landscape of
pharmacogenomic interactions in cancer. Cell 166, 740–
754.
32 Aksoy BA, Dancik V, Smith K, Mazerik JN, Ji Z,
Gross B, Nikolova O, Jaber N, Califano A, Schreiber
SL et al. (2017) CTD2 dashboard: a searchable web
interface to connect validated results from the Cancer
Target Discovery and Development Network. Database
2017, bax054.
33 Garcia-Alonso L, Iorio F, Matchan A, Fonseca N,
Jaaks P, Peat G, Pignatelli M, Falcone F, Benes CH,
Dunham I et al. (2018) Transcription factor activities
enhance markers of drug sensitivity in cancer. Cancer
Res 78, 769–780.
34 Peran I, Madhavan S, Byers SW & McCoy MD
(2018) Curation of the pancreatic ductal
adenocarcinoma subset of the cancer genome atlas is
essential for accurate conclusions about survival-
related molecular mechanisms. Clin Cancer Res 24,
3813–3819.
35 Cancer Genome Atlas Research Netwok, Weinstein JN,
Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C & Stuart JM (2013)
The cancer genome atlas pan-cancer analysis project.
Nat Genet 45, 1113–1120.
36 Metsalu T & Vilo J (2015) ClustVis: a web tool for
visualizing clustering of multivariate data using
Principal Component Analysis and heatmap. Nucleic
Acids Res 43, W566–W570.
37 Muhar M, Ebert A, Neumann T, Umkehrer C, Jude J,
Wieshofer C, Rescheneder P, Lipp JJ, Herzog VA,
Reichholf B et al. (2018) SLAM-seq defines direct gene-
regulatory functions of the BRD4-MYC axis. Science
360, 800–805.
38 Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza
SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC,
Chung AH et al. (2015) Virtual microdissection
identifies distinct tumor- and stroma-specific subtypes
of pancreatic ductal adenocarcinoma. Nat Genet 47,
1168–1178.
39 Kuleshov MV, Jones MR, Rouillard AD, Fernandez
NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik
KM, Lachmann A et al. (2016) Enrichr: a
comprehensive gene set enrichment analysis web server
2016 update. Nucleic Acids Res 44, W90–W97.
40 Stockel D, Kehl T, Trampert P, Schneider L, Backes C,
Ludwig N, Gerasch A, Kaufmann M, Gessler M, Graf
N et al. (2016) Multi-omics enrichment analysis using
the GeneTrail2 web service. Bioinformatics 32, 1502–
1508.
41 Benjamini Y, Drai D, Elmer G, Kafkafi N & Golani I
(2001) Controlling the false discovery rate in behavior
genetics research. Behav Brain Res 125, 279–284.
42 von Burstin J, Eser S, Paul MC, Seidler B, Brandl M,
Messer M, von Werder A, Schmidt A, Mages J, Pagel
P et al. (2009) E-cadherin regulates metastasis of
pancreatic cancer in vivo and is suppressed by a
SNAIL/HDAC1/HDAC2 repressor complex.
Gastroenterology 137, 361–371.
43 Ossewaarde JM, de Vries A, Bestebroer T & Angulo
AF (1996) Application of a Mycoplasma group-specific
PCR for monitoring decontamination of Mycoplasma-
infected Chlamydia sp. strains. Appl Environ Microbiol
62, 328–331.
44 Schonhuber N, Seidler B, Schuck K, Veltkamp C,
Schachtler C, Zukowska M, Eser S, Feyerabend TB,
Paul MC, Eser P et al. (2014) A next-generation dual-
recombinase system for time- and host-specific targeting
of pancreatic cancer. Nat Med 20, 1340–1347.
45 de Alboran IM, O’Hagan RC, Gartner F, Malynn B,
Davidson L, Rickert R, Rajewsky K, DePinho RA &
Alt FW (2001) Analysis of C-MYC function in normal
cells via conditional gene-targeted mutation. Immunity
14, 45–55.
46 Diersch S, Wirth M, Schneeweis C, Jors S, Geisler F,
Siveke JT, Rad R, Schmid RM, Saur D, Rustgi AK
et al. (2016) Kras(G12D) induces EGFR-MYC cross
signaling in murine primary pancreatic ductal epithelial
cells. Oncogene 35, 3880–3886.
47 Christensen CL, Kwiatkowski N, Abraham BJ,
Carretero J, Al-Shahrour F, Zhang T, Chipumuro E,
Herter-Sprie GS, Akbay EA, Altabef A et al. (2014)
Targeting transcriptional addictions in small cell lung
cancer with a covalent CDK7 inhibitor. Cancer Cell 26,
909–922.
48 Mueller S, Engleitner T, Maresch R, Zukowska M,
Lange S, Kaltenbacher T, Konukiewitz B, Ollinger R,
Zwiebel M, Strong A et al. (2018) Evolutionary routes
and KRAS dosage define pancreatic cancer phenotypes.
Nature 554, 62–68.
49 Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K,
Figueroa EF, O’Kane GM, Connor AA, Denroche RE,
Grant RC, McLeod J et al. (2020) Transcription
phenotypes of pancreatic cancer are driven by genomic
events during tumor evolution. Nat Genet 52, 231–240.
50 Schaub FX, Dhankani V, Berger AC, Trivedi M,
Richardson AB, Shaw R, Zhao W, Zhang X, Ventura
A, Liu Y et al. (2018) Pan-cancer alterations of the
MYC oncogene and its proximal network across the
cancer genome atlas. Cell Syst 6, 282–300.
3061Molecular Oncology 14 (2020) 3048–3064 ª 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
K. Lankes et al. Vulnerabilities in an aggressive PDAC subtype
51 Madden E, Logue SE, Healy SJ, Manie S& Samali A
(2019) The role of the unfolded protein response in
cancer progression: from oncogenesis to
chemoresistance. Biol Cell 111, 1–17.
52 Wirth M, Stojanovic N, Christian J, Paul MC, Stauber
RH, Schmid RM, Hacker G, Kramer OH, Saur D&
Schneider G (2014) MYC and EGR1 synergize to trigger
tumor cell death by controlling NOXA and BIM
transcription upon treatment with the proteasome
inhibitor bortezomib. Nucleic Acids Res 42, 10433–10447.
53 Davenport EL, Moore HE, Dunlop AS, Sharp SY,
Workman P, Morgan GJ & Davies FE (2007) Heat
shock protein inhibition is associated with activation of
the unfolded protein response pathway in myeloma
plasma cells. Blood 110, 2641–2649.
54 Gallerne C, Prola A & Lemaire C (2013) Hsp90 inhibition
by PU-H71 induces apoptosis through endoplasmic
reticulum stress and mitochondrial pathway in cancer cells
and overcomes the resistance conferred by Bcl-2. Biochim
Biophys Acta 1833, 1356–1366.
55 Vekaria PH, Home T, Weir S, Schoenen FJ & Rao R
(2016) Targeting p97 to disrupt protein homeostasis in
cancer. Front Oncol 6, 181.
56 Magnaghi P, D’Alessio R, Valsasina B, Avanzi N,
Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U,
Orrenius C et al. (2013) Covalent and allosteric
inhibitors of the ATPase VCP/p97 induce cancer cell
death. Nat Chem Biol 9, 548–556.
57 Sodir NM, Kortlever RM, Barthet VJA, Campos T,
Pellegrinet L, Kupczak S, Anastasiou P, Swigart LB,
Soucek L, Arends MJ et al. (2020) MYC instructs and
maintains pancreatic adenocarcinoma phenotype.
Cancer Discov 10, 588–607.
58 Biederstadt A, Hassan Z, Schneeweis C, Schick M,
Schneider L, Muckenhuber A, Hong Y, Siegers G,
Nilsson L, Wirth M et al. (2020) SUMO pathway
inhibition targets an aggressive pancreatic cancer
subtype. Gut 69, 1472–1482.
59 Fraunhoffer NA, Abuelafia AM, Bigonnet M, Gayet O,
Roques J, Telle E, Santofimia-Castano P, Borrello MT,
Chuluyan E, Dusetti N et al. (2020) Evidencing a
pancreatic ductal adenocarcinoma subpopulation
sensitive to the proteasome inhibitor carfilzomib. Clin
Cancer Res 26, 5506–5519.
60 Liu Y, Awadia S, Delaney A, Sitto M, Engelke CG,
Patel H, Calcaterra A, Zelenka-Wang S, Lee H,
Contessa J et al. (2020) UAE1 inhibition mediates the
unfolded protein response, DNA damage and caspase-
dependent cell death in pancreatic cancer. Transl Oncol
13, 100834.
61 Wolpaw AJ & Dang CV (2018) MYC-induced
metabolic stress and tumorigenesis. Biochim Biophys
Acta Rev Cancer 1870, 43–50.
62 Barna M, Pusic A, Zollo O, Costa M, Kondrashov N,
Rego E, Rao PH & Ruggero D (2008) Suppression of
Myc oncogenic activity by ribosomal protein
haploinsufficiency. Nature 456, 971–975.
63 Hart LS, Cunningham JT, Datta T, Dey S, Tameire F,
Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M et al.
(2012) ER stress-mediated autophagy promotes Myc-
dependent transformation and tumor growth. J Clin
Invest 122, 4621–4634.
64 Nagy P, Varga A, Pircs K, Heged}us K & Juhasz G
(2013) Myc-driven overgrowth requires unfolded
protein response-mediated induction of autophagy and
antioxidant responses in Drosophila melanogaster. PLoS
Genet 9, e1003664.
65 Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X,
Talukdar M, Lu Y, Wang X, Hu DZ et al. (2018)
Pharmacological targeting of MYC-regulated IRE1/
XBP1 pathway suppresses MYC-driven breast cancer. J
Clin Invest 128, 1283–1299.
66 Xie H, Tang CH, Song JH, Mancuso A, Del Valle JR,
Cao J, Xiang Y, Dang CV, Lan R, Sanchez DJ et al.
(2018) IRE1alpha RNase-dependent lipid homeostasis
promotes survival in Myc-transformed cancers. J Clin
Invest 128, 1300–1316.
67 Genovese G, Carugo A, Tepper J, Robinson FS, Li L,
Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P
et al. (2017) Synthetic vulnerabilities of mesenchymal
subpopulations in pancreatic cancer. Nature 542, 362–
366.
68 Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-
Paz N, Troska-Price T, Mulligan G, Chesi M,
Bergsagel Pl & Fonseca R (2011) Clinical and biological
implications of MYC activation: a common difference
between MGUS and newly diagnosed multiple
myeloma. Leukemia 25, 1026–1035.
69 Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H,
Masszi T, Viterbo L, Pour L, Ganly P, Cavo M,
Langer C et al. (2020) c-MYC expression and maturity
phenotypes are associated with outcome benefit from
addition of ixazomib to lenalidomide-dexamethasone in
myeloma. Eur J Haematol 105, 35–46.
70 Chang CW, Chen YS, Tsay YG, Han CL, Chen YJ,
Yang CC, Hung KF, Lin CH, Huang TY, Kao SY
et al. (2018) ROS-independent ER stress-mediated
NRF2 activation promotes warburg effect to maintain
stemness-associated properties of cancer-initiating cells.
Cell Death Dis 9, 194.
71 Zinszner H, Kuroda M, Wang X, Batchvarova N,
Lightfoot RT, Remotti H, Stevens JL & Ron D (1998)
CHOP is implicated in programmed cell death in
response to impaired function of the endoplasmic
reticulum. Genes Dev 12, 982–995.
72 Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y,
Rivera K, Palm W, Wilson J, Sangar V, Hao Y,
Ohlund D et al. (2016) NRF2 promotes tumor
maintenance by modulating mRNA translation in
pancreatic cancer. Cell 166, 963–976.
3062 Molecular Oncology 14 (2020) 3048–3064 ª 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
Vulnerabilities in an aggressive PDAC subtype K. Lankes et al.
73 Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N,
Podar K, Mitsiades C, Munshi NC, Richardson PG,
Carrasco RD et al. (2009) Bortezomib induces
canonical nuclear factor-kappaB activation in multiple
myeloma cells. Blood 114, 1046–1052.
74 Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D,
Fanourakis G, Gu X, Bailey C, Joseph M, Libermann
TA, Treon SP et al. (2002) Molecular sequelae of
proteasome inhibition in human multiple myeloma cells.
Proc Natl Acad Sci USA 99, 14374–14379.
75 Fennell DA, Chacko A & Mutti L (2008) BCL-2 family
regulation by the 20S proteasome inhibitor bortezomib.
Oncogene 27, 1189–1197.
76 Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM,
Pickard MD, Menon S, Yu J, Driscoll DL, Lingaraj T
et al. (2010) Genome-wide siRNA screen for
modulators of cell death induced by proteasome
inhibitor bortezomib. Cancer Res 70, 4318–4326.
77 Chunduri NK & Storchova Z (2019) The diverse
consequences of aneuploidy. Nat Cell Biol 21, 54–62.
78 Nawrocki ST, Sweeney-Gotsch B, Takamori R &
McConkey DJ (2004) The proteasome inhibitor
bortezomib enhances the activity of docetaxel in
orthotopic human pancreatic tumor xenografts. Mol
Cancer Ther 3, 59–70.
79 Sloss CM, Wang F, Liu R, Xia L, Houston M,
Ljungman D, Palladino MA & Cusack JC Jr (2008)
Proteasome inhibition activates epidermal growth factor
receptor (EGFR) and EGFR-independent mitogenic
kinase signaling pathways in pancreatic cancer cells.
Clin Cancer Res 14, 5116–5123.
80 Marten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-
Toal M & Schmidt J (2008) Bortezomib is ineffective in
an orthotopic mouse model of pancreatic
adenocarcinoma. Mol Cancer Ther 7, 3624–3631.
81 Kawaguchi K, Igarashi K, Murakami T, Kiyuna T,
Lwin TM, Hwang HK, Delong JC, Clary BM, Bouvet
M, Unno M et al. (2017) MEK inhibitors cobimetinib
and trametinib, regressed a gemcitabine-resistant
pancreatic-cancer patient-derived orthotopic xenograft
(PDOX). Oncotarget 8, 47490–47496.
82 Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R,
Andrianov G, Bobrov E, Lysenko E, Skobeleva N,
Gabitova L, Restifo D et al. (2016) Screening of
conditionally reprogrammed patient-derived carcinoma
cells identifies ERCC3-MYC interactions as a target in
pancreatic cancer. Clin Cancer Res 22, 6153–6163.
83 Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer
P, Wiesenfeld M, Fitch TR, Steen P, Kim GP & Gill S
(2005) PS-341 and gemcitabine in patients with
metastatic pancreatic adenocarcinoma: a North Central
Cancer Treatment Group (NCCTG) randomized phase
II study. Ann Oncol 16, 1654–1661.
84 Wang J, Jiang J, Chen H, Wang L, Guo H, Yang L, Xiao
D, Qing G & Liu H (2019) FDA-approved drug screen
identifies proteasome as a synthetic lethal target in MYC-
driven neuroblastoma. Oncogene 38, 6737–6751.
85 Biliran H Jr, Banerjee S, Thakur A, Sarkar FH, Bollig A,
Ahmed F, Wu J, Sun Y & Liao JD (2007) c-Myc-induced
chemosensitization is mediated by suppression of cyclin
D1 expression and nuclear factor-kappa B activity in
pancreatic cancer cells. Clin Cancer Res 13, 2811–2821.
86 Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ,
Lanciault C, Sauer D, Link J, Pelz C, Heiser LM,
Morton JP et al. (2017) MYC regulates ductal-
neuroendocrine lineage plasticity in pancreatic ductal
adenocarcinoma associated with poor outcome and
chemoresistance. Nat Commun 8, 1728.
87 Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson
L, Ridgway RA, Huels D, Littler S, Schandl C et al.
(2015) MYC is a major determinant of mitotic cell fate.
Cancer Cell 28, 129–140.
88 Parasido E, Avetian GS, Naeem A, Graham G,
Pishvaian M, Glasgow E, Mudambi S, Lee Y,
Ihemelandu C, Choudhry M et al. (2019) The sustained
induction of c-MYC drives Nab-paclitaxel resistance in
primary pancreatic ductal carcinoma cells. Mol Cancer
Res 17, 1815–1827.
89 Manasanch EE & Orlowski RZ (2017) Proteasome
inhibitors in cancer therapy. Nat Rev Clin Oncol 14,
417–433.
90 Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y & Liu
P (2014) Efficacy of therapy with bortezomib in solid
tumors: a review based on 32 clinical trials. Future
Oncol 10, 1795–1807.
91 Thibaudeau TA & Smith DM (2019) A practical review
of proteasome pharmacology. Pharmacol Rev 71, 170–
197.
92 Deshantri AK, Metselaar JM, Zagkou S, Storm G,
Mandhane SN, Fens MHAM & Schiffelers RM (2019)
Development and characterization of liposomal
formulation of bortezomib. Int J Pharm X 1, 100011.
93 Best S, Hashiguchi T, Kittai A, Bruss N, Paiva C,
Okada C, Liu T, Berger A & Danilov AV (2019)
Targeting ubiquitin-activating enzyme induces ER
stress-mediated apoptosis in B-cell lymphoma cells.
Blood Adv 3, 51–62.
Supporting information
Additional supporting information may be found
online in the Supporting Information section at the end
of the article.
Fig. S1. Survival and Subtypes of common MYChigh
PDACs. A) Survival data of common MYChigh
PDACs of the ICGC dataset are displayed in a
Kaplan–Meier curve. P value of a log-rank test is
depicted. B) Percentage of squamous subtype of the
common MYChigh PDACs compared to the others.
Fisher Exact test: P < 0.0001. C) Venn diagram of
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PDAC identified as MYChigh by clustering of the genes
of the depicted signatures in the TCGA dataset. 16
PDACs were identified as common MYChigh PDACs.
D) Survival data of common MYChigh PDACs of the
TCGA dataset are displayed in a Kaplan–Meier curve.
E) Percentage of basal-like subtype of the common
MYChigh PDACs compared to the others. Fisher
Exact test: P < 0.05. F) GSEA of IMIM-PC1MYCER
cells treated with 4-OHT to activate MYC. Depicted
are HALLMARK and KEGG signature correspond-
ing to the tissue-based analysis corresponding to
Fig. 3D. The NES and the FDR q values are depicted.
Fig. S2. Association of MYC with perturbants of the
protein homeostasis. Sensitivities of human PDAC cell
lines from the PRISM repurposing primary screen
(19Q3) [30] of the depicted drug classes were divided
into quartiles and lines for the most sensitive quartile
were compared to the remaining cell lines of the com-
plete CCLE-PDAC dataset with a gene set enrichment
analysis using the GeneTrail2 1.6 web service. The
enrichment score was color-coded. ** adjust. P-
value < 0.01; **** adjust. P-value < 0.0001.
Table S1. Doubling time of PDAC cell lines used for
the drug screening experiment. Panc1, PaTu8988S,
DanG and PSN1 cells were seeded in 96 well plates at
a density of 3000 cells/well. After 24, 48, 72 and 96 h
viable cells were measured by MTT test to determine
doubling time of the cell lines.
Table S2. Complete list of the response to compounds
used in the drug screen. PSN1, Panc1, PaTu8988S and
DanG cells were treated with n = 129 compounds in bio-
logical and technical triplicates. Drug response as well as
mean of MYC high and mean of MYC low are displayed.
Table S3. Pathways associated with MYC in common
MYChigh PDAC. GSEA of pathways enriched in com-
mon MYChigh PDAC of the ICGC and the TCGA
dataset.
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